Exact Sciences Corp.
Latest From Exact Sciences Corp.
Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.
Pacts In Medtech: Myriad/Pfizer Deal Headlines Oncology-Heavy List Of Deals In September And October
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were sealed in September and October 2018.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech highlights notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we look at industry pacts that were sealed in July and August 2018.
FDA has approved FoundationOne CDx, the first next-generation sequencing test to clear the agency's expedited access pathway as a breakthrough-designated diagnostic. The companion diagnostic also nabbed a positive national Medicare coverage propose simultaneously thanks to the FDA/CMS Parallel Review Program.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Laboratory Testing Services
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Exact Sciences Corp.
- Senior Management
Kevin T Conroy, CEO
Jeff Elliott, CFO
Graham P Lidgard, PhD, CSO
Barry Berger, MD, Co-CMO
Paul Limburg, Co-CMO
- Contact Info
Exact Sciences Corp.
Phone: (608) 284-5700
441 Charmany Dr.
Madison, WI 53719
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.